As with any therapeutic, the design of the manufacturing process is central in being able to efficiently produce, and provide patients with, quality treatments. For cell and gene therapies (CGTs), however, the challenges in optimizing this process are unique due to the complex nature of the technology which is ever evolving and means dealing with high degrees of variability.
It’s a topic which is comprised of a few recurring debates that can often polarize industry experts into different camps. Here, I will introduce some of the debates I have...